Translational Therapeutics Accelerator (TRx)
Pre-Proposal Applications for the 2024 - 2025 cycle are now closed.
The Irving Institute Accelerate Program is a therapeutic development accelerator platform that plays a central role in translating the outstanding basic science discoveries at Columbia University into commercial therapeutics. Through our Translational Therapeutics (TRx) accelerator award, we focus on providing funding, education, partnership and mentorship to Columbia Investigators, with a goal of advancing novel therapies from the lab towards the clinic. Advice and project guidance will be provided by a steering committee of academic and industry experts in the field of drug development.
Timeline
Cumulative Success Metrics (TRx)
- 6 cycles administered
- 84 applications received
- 84 teams admitted to/went through accelerator
- 50 awards given
- Over $1.43M in funding awarded by TRx to teams
- $84.7M in funding awarded to teams by external sources
2019-2020 Founders' Spotlights
Student Venture Associate Grace Kim had a chance to virtually sit down with TRx cohort member and Scientific Director of the Harris Wang lab, Kristin Beiswenger. Based on research from the lab of Dr. Wang, the research team are developing a platform technology for an orally delivered programmable gene modulator therapeutic.